PeptideStack
5.2kquestions
20kanswers
220users

Is there any published stability data for a GLP-1 receptor agonist at 30 °C?

Asked 15 Dec 2025Modified 6 months agoViewed 7.4k times
10

Details up front: a GLP-1 receptor agonist · 30 °C.

I am asking for verification rather than opinion, ideally with something I can read myself.

It is possible the evidence exists and I am searching for the wrong term.

Is this actually true, and what is the evidence?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
shareeditfollowflag
SI
askedsample_id17k2715 Dec 2025

4 Answers

Sorted by votes
25

Probably not at 30 °C specifically, because that is not where stability programmes take their readings. Accelerated work is conventionally run at 25 °C and 40 °C, with the refrigerated condition as the control, so 30 °C sits between or beyond the published points and what you will find is bracketing rather than a measurement. 30 °C is 25 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 5.7 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. Whatever you find, check what was measured before you use it: a paper reporting purity at 30 °C has not measured content, and the two fail at different rates for different reasons.

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Degradation pathway by condition

PathwayDominant whenDetected by
DeamidationSolution, neutral to alkaline pHRP-HPLC, +1 Da on MS
OxidationLight, trace metals, peroxidesRP-HPLC, +16 Da on MS
HydrolysisSolution, extremes of pHRP-HPLC, fragment masses
AggregationAgitation, interfaces, high concentrationSEC, visual haze; often invisible on RP-HPLC
Freeze-concentration damageFreeze-thaw of buffered solutionSEC, loss of recovered content

The relevant detail is that adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Cold, dry, dark, still. Those four words cover most of the mitigation.

edited 24 Jan 2026 by Dr_Colm_Fitzhenry — tightened the wording; no substantive change

shareimprove this answerflag
DF
answeredDr_Colm_Fitzhenry69k24715 Jan 2026
6I have kept vials both ways for a year and this matches what I saw. – marta_okonkwo 2 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
18

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

At dilute concentrations, suspect adsorption before you suspect chemistry.

shareimprove this answerflag
DF
answeredDr_Nadia_Farsi104k24720 Jan 2026
4Adding for future readers: the domestic leg after delivery is the part you control. – lukas_sedlacek 9 months ago
3Adding a vote because this deserves more of them. – plate_count_9k 8 months ago
add a comment
14

Start with the sequence, because which pathways are available depends on which residues are present.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

Sequence decides which pathways are even available. Check the residues.

shareimprove this answerflag
RP
answeredrhian_prydderch23k276 Feb 2026
12

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Sequence determines which pathways apply, so general statements are general.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

shareimprove this answerflag
DF
answeredDr_Colm_Fitzhenry69k24726 Jan 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.